{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T02:06:19Z","timestamp":1787191579267,"version":"build-2736575974"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-16-C-0009, HDTRA-18-1-0035, HDTRA-18-1-0036"],"award-info":[{"award-number":["HDTRA1-16-C-0009, HDTRA-18-1-0035, HDTRA-18-1-0036"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vaccines are among the most cost-effective public health measures for controlling infectious diseases. <jats:italic>Coxiella burnetii<\/jats:italic> is the etiological agent of Q fever, a disease with a wide clinical spectrum that ranges from mild symptoms, such as fever and fatigue, to more severe disease, such as pneumonia and endocarditis. The formalin-inactivated whole-cell vaccine Q-VAX<jats:sup>\u00ae<\/jats:sup> contains hundreds of antigens and confers lifelong protection in humans, but prior sensitization from infection or vaccination can result in deleterious reactogenic responses to vaccination. Consequently, there is great interest in developing non-reactogenic alternatives based on adjuvanted recombinant proteins. In this study, we aimed to develop a multivalent vaccine that conferred protection with reduced reactogenicity. We hypothesized that a multivalent vaccine consisting of multiple antigens would be more immunogenic and protective than a monovalent vaccine owing to the large number of potential protective antigens in the <jats:italic>C. burnetii<\/jats:italic> proteome. To address this, we identified immunogenic T and B cell antigens, and selected proteins were purified to evaluate with a combination adjuvant (IVAX-1), with or without <jats:italic>C. burnetii<\/jats:italic> lipopolysaccharide (LPS) in immunogenicity studies <jats:italic>in vivo<\/jats:italic> in mice and in a Hartley guinea pig intratracheal aerosol challenge model using <jats:italic>C. burnetii<\/jats:italic> strain NMI RSA 493. The data showed that multivalent vaccines are more immunogenic than monovalent vaccines and more closely emulate the protection achieved by Q-VAX. Although six antigens were the most immunogenic, we also discovered that multiplexing beyond four antigens introduces detectable reactogenicity, indicating that there is an upper limit to the number of antigens that can be safely included in a multivalent Q-fever vaccine. <jats:italic>C. burnetii<\/jats:italic> LPS also demonstrates efficacy as a vaccine antigen in conferring protection in an otherwise monovalent vaccine formulation, suggesting that its addition in multivalent vaccines, as demonstrated by a quadrivalent formulation, would improve protective responses.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1192821","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:18:33Z","timestamp":1689668313000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Multivalent vaccines demonstrate immunogenicity and protect against Coxiella burnetii aerosol challenge"],"prefix":"10.3389","volume":"14","author":[{"given":"Sharon","family":"Jan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alycia P.","family":"Fratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiin","family":"Felgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E.","family":"Hernandez-Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Algimantas","family":"Jasinskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medalyn","family":"Supnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Felgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Huw","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1071\/NB07057","article-title":"A review of the efficacy of human q fever vaccine registered in Australia","volume-title":"Database of abstracts of reviews of effects (DARE): quality-assessed reviews","author":"Chiu","year":"2007"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.008","article-title":"Effectiveness of the q fever vaccine: a meta-analysis","volume":"29","author":"Gefenaite","year":"2011","journal-title":"Vaccine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Pasquale","year":"2015","journal-title":"Vaccines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1495565","article-title":"Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention","volume":"17","author":"Lecrenier","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG adjuvant 1018: a case study","volume-title":"Vaccine adjuvants: methods and protocols","author":"Campbell","year":"2017"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.08.005","article-title":"Immunogenicity and safety of a 2-dose hepatitis b vaccine, HBsAg\/CpG 1018, in persons with diabetes mellitus aged 60\u201370 years","volume":"37","author":"Hyer","year":"2019","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692151","article-title":"Administration of multivalent influenza virus recombinant hemagglutinin vaccine in combination-adjuvant elicits broad reactivity beyond the vaccine components","volume":"12","author":"Hernandez-Davies","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577823","article-title":"MPL adjuvant contains competitive antagonists of human TLR4","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000868","article-title":"Toward precision adjuvants: optimizing science and safety","volume":"32","author":"Nanishi","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020962050","article-title":"Heplisav-b: a hepatitis b vaccine with a novel adjuvant","volume":"55","author":"Champion","year":"2021","journal-title":"Ann Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.molimm.2018.03.001","article-title":"A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model","volume":"96","author":"Choubini","year":"2018","journal-title":"Mol Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2018.0022","article-title":"Advancing freund\u2019s and AddaVax adjuvant regimens using CpG oligodeoxynucleotides","volume":"37","author":"Hawksworth","year":"2018","journal-title":"Monoclon Antibodies Immunodiagn Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-4315-1_6","article-title":"Proteome of Coxiella burnetii","volume-title":"Coxiella burnetii: recent advances and new perspectives in research of the q fever bacterium","author":"Ihnatko","year":"2012"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2011.05.017","article-title":"Proteomic comparison of virulent phase I and avirulent phase II of Coxiella burnetii, the causative agent of q fever","volume":"74","author":"Skultety","year":"2011","journal-title":"J Proteomics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00613-12","article-title":"Long-term immune responses to Coxiella burnetii after vaccination","volume":"20","author":"Kersh","year":"2013","journal-title":"Clin Vaccine Immunol CVI"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2014.11.003","article-title":"An overview of bioinformatics tools for epitope prediction: implications on vaccine development","volume":"53","author":"Soria-Guerra","year":"2015","journal-title":"J BioMed Inform"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.92","article-title":"Multi-epitope vaccines: a promising strategy against tumors and viral infections","volume":"15","author":"Zhang","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"fuaa054","DOI":"10.1093\/femsre\/fuaa054","article-title":"Vaccines for multidrug resistant gram negative bacteria: lessons from the past for guiding future success","volume":"45","author":"L\u00f3pez-Siles","year":"2021","journal-title":"FEMS Microbiol Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.micpath.2018.11.012","article-title":"Determination of immunodominant scaffolds of Com1 and OmpH antigens of Coxiella burnetii","volume":"126","author":"Jaydari","year":"2019","journal-title":"Microb Pathog"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6C.1.1","DOI":"10.1002\/9780471729259.mc06c01s15","article-title":"Laboratory maintenance of Coxiella burnetii","volume":"15","author":"Samuel","year":"2009","journal-title":"Curr Protoc Microbiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.8b00823","article-title":"Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses","volume":"5","author":"Albin","year":"2019","journal-title":"ACS Cent Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0931379100","article-title":"Complete genome sequence of the q-fever pathogen Coxiella burnetii","volume":"100","author":"Seshadri","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201000064","article-title":"Genome-wide profiling of humoral immune response to Coxiella burnetii infection by protein microarray","volume":"10","author":"Vigil","year":"2010","journal-title":"Proteomics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"M110.006304","DOI":"10.1074\/mcp.M110.006304","article-title":"Profiling the humoral immune response of acute and chronic q fever by protein microarray","volume":"10","author":"Vigil","year":"2011","journal-title":"Mol Cell Proteomics MCP"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653092","article-title":"Subunit vaccines using TLR triagonist combination adjuvants provide protection against Coxiella burnetii while minimizing reactogenic responses","volume":"12","author":"Fratzke","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400663","article-title":"T Cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and non-virion association","volume":"193","author":"Davies","year":"2014","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00300-08","article-title":"Candidate antigens for q fever serodiagnosis revealed by immunoscreening of a Coxiella burnetii protein microarray","volume":"15","author":"Beare","year":"2008","journal-title":"Clin Vaccine Immunol CVI"},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2180-12-35","article-title":"Potential serodiagnostic markers for q fever identified in Coxiella burnetii by immunoproteomic and protein microarray approaches","volume":"12","author":"Xiong","year":"2012","journal-title":"BMC Microbiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.043513-0","article-title":"Immunoreactive Coxiella burnetii nine mile proteins separated by 2D electrophoresis and identified by tandem mass spectrometry","volume":"157","author":"Deringer","year":"2011","journal-title":"Microbiology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0621-4","article-title":"Identification of protein candidates for the serodiagnosis of q fever endocarditis by an immunoproteomic approach","volume":"28","author":"Sekeyov\u00e1","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/ac800788k","article-title":"Detection and identification of Coxiella burnetii based on the mass spectrometric analyses of the extracted proteins","volume":"80","author":"Hernychova","year":"2008","journal-title":"Anal Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/prca.201200096","article-title":"The contribution of proteomics towards deciphering the enigma of Coxiella burnetii","volume":"7","author":"Vranakis","year":"2013","journal-title":"Proteomics \u2013 Clin Appl"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10969-005-2664-4","article-title":"Enhanced expression and purification of membrane proteins by SUMO fusion in escherichia coli","volume":"6","author":"Zuo","year":"2005","journal-title":"J Struct Funct Genomics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2014.02.020","article-title":"Protocol for sortase-mediated construction of DNA\u2013protein hybrids and functional nanostructures","volume":"67","author":"Koussa","year":"2014","journal-title":"Methods"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/ja050690c","article-title":"High-affinity adaptors for switchable recognition of histidine-tagged proteins","volume":"127","author":"Lata","year":"2005","journal-title":"J Am Chem Soc"},{"key":"B38","doi-asserted-by":"publisher","first-page":"107944","DOI":"10.1016\/j.exppara.2020.107944","article-title":"Measuring of IgG2c isotype instead of IgG2a in immunized C57BL\/6 mice with plasmodium vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response","volume":"216","author":"Nazeri","year":"2020","journal-title":"Exp Parasitol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1086\/317537","article-title":"Type 1\/Type 2 immunity in infectious diseases","volume":"32","author":"Spellberg","year":"2001","journal-title":"Clin Infect Dis"},{"key":"B40","article-title":"The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1\/Th2 cytokine balance","volume":"82","author":"Hernandez-Pando","year":"1994","journal-title":"Immunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01767-06","article-title":"T Cells are essential for bacterial clearance, and gamma interferon, tumor necrosis factor alpha, and b cells are crucial for disease development in Coxiella burnetii infection in mice","volume":"75","author":"Andoh","year":"2007","journal-title":"Infect Immun"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9198","DOI":"10.1038\/s41598-022-12727-y","article-title":"Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants","volume":"12","author":"Hernandez-Davies","year":"2022","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.12.8372","article-title":"Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in BALB\/c Mice1","volume":"179","author":"Zhang","year":"2007","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/1471-2334-13-488","article-title":"Human dose response relation for airborne exposure to Coxiella burnetii","volume":"13","author":"Brooke","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B45","article-title":"Animal models of q fever (Coxiella burnetii)","volume":"63","author":"Bewley","year":"2013","journal-title":"Comp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00763-06","article-title":"Clinical and pathologic changes in a Guinea pig aerosol challenge model of acute q fever","volume":"74","author":"Russell-Lodrigue","year":"2006","journal-title":"Infect Immun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.8b01473","article-title":"Impact of polymer-TLR-7\/8 agonist (Adjuvant) morphology on the potency and mechanism of CD8 T cell induction","volume":"20","author":"Lynn","year":"2019","journal-title":"Biomacromolecules"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.754712","article-title":"Coxiella burnetii whole cell vaccine produces a Th1 delayed-type hypersensitivity response in a novel sensitized mouse model","volume":"12","author":"Fratzke","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886810","article-title":"Immunogenicity and reactogenicity in q fever vaccine development","volume":"13","author":"Fratzke","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1749-6632.1990.tb42220.x","article-title":"The immune response to phase I and phase II Coxiella burnetii antigens as measured by Western immunoblottinga","volume":"590","author":"Blondeau","year":"1990","journal-title":"Ann N Y Acad Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00484-3","article-title":"Distribution of immunoglobulin G (IgG) and a (IgA) subclasses following q fever vaccination with soluble phase I Coxiella burnetii extract","volume":"18","author":"Camacho","year":"2000","journal-title":"Vaccine"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-19-3-281","article-title":"Antibody responses in acute and chronic q fever and in subjects vaccinated against q fever","volume":"19","author":"WORSWICK","year":"1985","journal-title":"J Med Microbiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/iai.14.4.1087-1096.1976","article-title":"Electron microscopic study on the interaction between normal guinea pig peritoneal macrophages and Coxiella burnetii","volume":"14","author":"Kishimoto","year":"1976","journal-title":"Infect Immun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00101-10","article-title":"Role of CD4+ and CD8+ T cells in clearance of primary pulmonary infection with Coxiella burnetii","volume":"78","author":"Read","year":"2010","journal-title":"Infect Immun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.4.2259","article-title":"IFN-\u03b3-Mediated control of Coxiella burnetii survival in monocytes: the role of cell apoptosis and TNF1","volume":"162","author":"Dellacasagrande","year":"1999","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.9.5140-5147.2002","article-title":"Nitric oxide inhibits Coxiella burnetii replication and parasitophorous vacuole maturation","volume":"70","author":"Howe","year":"2002","journal-title":"Infect Immun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4488","article-title":"Coxiella\u2008burnetii survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN-\u03b3 mediates its restoration and bacterial Killing1","volume":"169","author":"Ghigo","year":"2002","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00411-16","article-title":"Murine alveolar macrophages are highly susceptible to replication of Coxiella burnetii phase II in vitro","volume":"84","author":"Fernandes","year":"2016","journal-title":"Infect Immun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.3.1225-1233.2003","article-title":"Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages","volume":"71","author":"Zamboni","year":"2003","journal-title":"Infect Immun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1814745","article-title":"Diagnosis and management of hypersensitivity reactions to vaccines","volume":"16","author":"Sarti","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B61","article-title":"Type IV hypersensitivity reaction","volume-title":"StatPearls","author":"Marwa","year":"2022"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201622","article-title":"Development of a lipopolysaccharide-targeted peptide mimic vaccine against q fever","volume":"189","author":"Peng","year":"2012","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.012","article-title":"Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines","volume":"41","author":"Dold","year":"2023","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/iai.55.5.1144-1150.1987","article-title":"Comparative virulence of intra- and interstrain lipopolysaccharide variants of Coxiella burnetii in the guinea pig model","volume":"55","author":"Moos","year":"1987","journal-title":"Infect Immun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/iai.56.4.802-807.1988","article-title":"Steric hindrance of antibody binding to surface proteins of coxiella burnetti by phase I lipopolysaccharide","volume":"56","author":"Hackstadt","year":"1988","journal-title":"Infect Immun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2014.00182","article-title":"Coxiella burnetii lipopolysaccharide blocks p38\u03b1-MAPK activation through the disruption of TLR-2 and TLR-4 association","volume":"4","author":"Conti","year":"2015","journal-title":"Front Cell Infect Microbiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/ijms18122509","article-title":"Coxiella burnetii lipopolysaccharide: what do we know","volume":"18","author":"Abnave","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.1.160-164.2000","article-title":"Coxiella burnetii survives in monocytes from patients with q fever endocarditis: involvement of tumor necrosis factor","volume":"68","author":"Dellacasagrande","year":"2000","journal-title":"Infect Immun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.6.3695","article-title":"Lipopolysaccharide from Coxiella burnetii is involved in bacterial phagocytosis, filamentous actin reorganization, and inflammatory responses through toll-like receptor 41","volume":"172","author":"Honstettre","year":"2004","journal-title":"J Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2011.00852.x","article-title":"Effects of Coxiella burnetii on MAPKinases phosphorylation","volume":"64","author":"Boucherit","year":"2012","journal-title":"FEMS Immunol Med Microbiol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.10.7101","article-title":"MAPK p38 regulates transcriptional activity of NF-\u03baB in primary human astrocytes via acetylation of p65","volume":"179","author":"Saha","year":"2007","journal-title":"J Immunol Baltim Md"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01849","article-title":"Tumor necrosis factor receptor-associated factor regulation of nuclear factor \u03baB and mitogen-activated protein kinase pathways","volume":"9","author":"Shi","year":"2018","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq037","article-title":"Coxiella burnetii antigen-stimulated dendritic cells mediated protection against Coxiella burnetii in BALB\/c mice","volume":"203","author":"Wei","year":"2011","journal-title":"J Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2500From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2020","journal-title":"Chem Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-019-0110-z","article-title":"Recent advances in the production of recombinant glycoconjugate vaccines","volume":"4","author":"Kay","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coi.2018.04.011","article-title":"Antibody-based vaccine strategies against intracellular pathogens","volume":"53","author":"Casadevall","year":"2018","journal-title":"Curr Opin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1192821\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T08:18:43Z","timestamp":1689668323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1192821\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2023.1192821"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1192821","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"article-number":"1192821"}}